TP53 and neoplasm: After studying the impact of the duration of adjuvant therapy on prevalence of alterations in TP53, which is prognostic40, and ESR1, which is associated with AI-resistance, we evaluated changes in the tumor genomic landscape following first-line (1L) treatment and in later lines (2L+).